Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Neurological sequela and disruption of neuron-glia homeostasis in SARS-CoV-2 infection

Masha G. Savelieff a, Eva L. Feldman a,b,c, Amro M. Stino b,c,*

Keywords: Axon, Astrocyte, COVID-19, Cytokine storm, Extracellular vesicles, Immune system, Microglia, Neuron, Oligodendrocyte

ABSTRACT

The coronavirus disease 2019 (COVID-19) pandemic is responsible for 267 million infections and over 5 million deaths globally. COVID-19 is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), a single-stranded RNA beta-coronavirus, which causes a systemic inflammatory response, multi-organ damage, and respiratory failure requiring intubation in serious cases. SARS-CoV-2 can also trigger neurological conditions and syndromes, which can be long-lasting and potentially irreversible. Since COVID-19 infections continue to mount, the burden of SARS-CoV-2-induced neurologic sequelae will rise in parallel. Therefore, understanding the spectrum of neurological clinical presentations in SARS-CoV-2 is needed to manage COVID-19 patients, facilitate diagnosis, and expedite earlier treatment to improve outcomes. Furthermore, a deeper knowledge of the neurological SARS-CoV-2 pathomechanisms could uncover potential therapeutic targets to prevent or mitigate neurologic damage secondary to COVID-19 infection. Evidence indicates a multifaceted pathology involving viral neurotropism and direct neuroinvasion along with cytokine storm and neuroinflammation leading to nerve injury. Importantly, pathological processes in neural tissue are non-cell autonomous and occur through a concerted breakdown in neuron-glia homeostasis, spanning neuron axonal damage, astrogliosis, microgliosis, and impaired neuron-glia communication. A clearer mechanistic and molecular picture of neurological pathology in SARS-CoV-2 may lead to effective therapies that prevent or mitigate neural damage in patients contracting and developing severe COVID-19 infection.

1. Introduction

Late in 2019, a new coronavirus emerged, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), triggering the coronavirus disease 2019 (COVID-19) pandemic. Globally, 267 million individuals have contracted SARS-CoV-2, which has killed over 5 million people, as of December 2021 (https://coronavirus.jhu.edu/map.html, n.d.). SARS-CoV-2 is a single-stranded RNA beta-coronavirus, which causes a systemic inflammatory response, multi-organ damage, and respiratory failure requiring intubation in serious cases. The virus is especially dangerous to older populations and patients with co-morbidities, such as obesity and diabetes (Feldman et al., 2020). The pathophysiology remains incompletely understood; however, neurological involvement is increasingly evident. This has important health implications for SARS-CoV-2 survivors, due to the frequent long-lasting and potentially irreversible nature of neurologic sequelae. Moreover, as infections continue to rise, so will the burden of SARS-CoV-2-induced neurologic complications.

Therefore, understanding the spectrum of neurological disorders in response to SARS-CoV-2 is needed to manage COVID-19 patients (Ellul et al., 2020). This will facilitate recognition of nervous system injury secondary to SARS-CoV-2, which could expedite earlier treatment to improve outcomes. Furthermore, a clearer understanding of the neurological SARS-CoV-2 pathomechanisms could uncover potential therapeutic targets. To date, the evidence suggests SARS-CoV-2-triggered neurological damage occurs through several avenues. First, the virus exhibits neurotropism, enabling direct invasion of neural tissue (Song et al., 2021). Second, systemic cytokine storm and a hyperactive inflammatory immune response secondary to viral infection, can cause nerve injury (Thepmankorn et al., 2021). Additionally, local induction of neuroinflammation within the central nervous system (CNS) also contributes to neuronal damage. Importantly, pathological processes in...
neural tissue are non-cell autonomous and occur through a concerted breakdown in neuron-glia homeostasis. These processes span neuron axonal damage, astrogliosis, microgliosis, and impaired neuron-glia communication.

This review will cover the topic of SARS-CoV-2-triggered loss of neuron-glia homeostasis. We will describe the breadth of neurological presentation in COVID-19 patients and describe evidence from clinical and autopsy studies of virally induced neuronal loss, endothelial astrogliosis, and neuroinflammation. We will also outline in vitro and animal research demonstrating putative viral entry routes and neurotropism, followed by a focus on neuron-glia interactions. Lastly, we will round up the discussion with potential therapeutic avenues based on currently known SARS-CoV-2 pathophysiology.

2. Neurological manifestation in COVID-19 patients

The SARS-CoV-2 pandemic precipitated a now recognized global increase in the prevalence of well-characterized and rare neurologic sequelae of the CNS and peripheral nervous systems (PNS) in response to viral illness (Mao et al., 2020). One United Kingdom (UK) study systematically documented the various neurologic syndromes experienced by COVID-19 survivors. Neurologic complications included encephalopathy, encephalitis with documented CNS inflammatory changes, ischemic stroke, and Guillain-Barré Syndrome (GBS), among other miscellaneous syndromes (Paterson et al., 2020). The postulated SARS-CoV-2-mediated pathomechanisms for CNS and PNS injury comprise direct neurotropic invasion and parainfectious endothelial dysfunction, coagulopathy, hyperinflammation, and autoimmunity (Fig. 1A) (Mehta et al., 2020; Zubair et al., 2020).

Regarding endothelial dysfunction and coagulopathy, a prospective Belgian study of post-mortem brain magnetic resonance (n = 62) revealed subcortical micro- and macrobleeds, likely due to blood-brain barrier (BBB) breakdown (Coolen et al., 2020). This endothelial dysfunction, with or without direct viral infection, may underlie SARS-CoV-2-mediated CNS injury. SARS-CoV-2 related stroke syndromes tend to occur in the setting of markedly elevated D-dimer levels, frequently with concurrent large vessel and systemic venous thromboembolic events (Beyrouti et al., 2020). Notably, young patients suffer higher-than-expected stroke incidences, typically large vessel, which appears to implicate coagulopathy and endothelial dysfunction (Oxley et al., 2020). Antiphospholipid antibody syndrome from hypercoagulability has occurred in some cases, likely linked to pro-inflammatory cytokine states (Zhang et al., 2020).

In terms of immune response, post-mortem examination of six patients in Germany showed encephalitic and meningeal changes, with evidence of brainstem perivascular and inflammatory changes associated with neuronal loss (van Weyhern et al., 2020). Encephalitis, in particular, has figured prominently in SARS-CoV-2-mediated CNS injury. Acute demyelinating encephalomyelitis is a rare disorder lacking clear evidence of direct causality in SARS-CoV-2 injury. One autopsy study, however, illustrates some of the CNS inflammatory patterns seen in COVID-19-induced CNS injury, and sheds valuable insight into putative pathomechanisms. This post-mortem evaluation revealed hemorrhagic white matter lesions in the bilateral hemispheres, mostly subcortically, with macrophagic foci surrounding small vessels along with myelin breakdown and axonal damage (Reichard et al., 2020). Additionally,

Fig. 1. SARS-CoV-2-induced neurological manifestations.
(A) SARS-CoV-2-induced neurologic complications can affect the CNS and PNS. Damage to the brain stem and autonomic nervous systems can lead to respiratory and cardiac dysfunction. Severe COVID-19 patients exhibit systemic inflammation, marked by elevated white blood cells and pro-inflammatory cytokines. Antibodies specific to PNS injury can be detected in blood, including IgG, anti-GM1, anti-GD1a, and anti-GD1b. (B) SARS-CoV-2 binds to ACE2 (shown in figure) or NRP1 receptors, and a serine protease, e.g., TMPRSS2, cleaves the complex, leading to viral internalization. (C) The virus infects sustentacular cells of the nasal epithelium. ACE2, angiotensin-converting enzyme 2; BBB, blood-brain barrier; CNS, central nervous system; GBS, Guillain-Barré Syndrome; NRP1, neuropilin-1; PNS, peripheral nervous system; TMPRSS2, transmembrane serine protease 2. Created, in part, with BioRender.com.
there was generalized widespread glial fibrillary acidic protein (GFAP) positive staining, indicative of astroglisis, in white matter, but not in the hemorrhagic lesions. Furthermore, separate radiologic case reports of SARS-CoV-2-induced encephalitis document symmetric focal involvement of the bilateral thalami (Poyiadji et al., 2020) and the brainstem (Dixon et al., 2020). The neurologic UK study did not detect antibodies in COVID-19 patients with autoimmune encephalitis (Paterson et al., 2020). However, a number of studies have reported myelin oligodendrocyte glycoprotein (MOG)-associated demyelinating syndrome (Woodhull et al., 2020; Sinha et al., 2021), encephalitis (Peters et al., 2021), and optic neuritis (Sawalha et al., 2020) in the SARS-CoV-2 setting.

In the CNS, most neurological SARS-CoV-2-related clinical experience has focused on GBS, and numerous cases have been described (Padroni et al., 2020; Sedaghat and Karimi, 2020; Tiet and Alsheikh, 2020). As with most pathogen-mediated GBS, autoimmune cross-reactivity or molecular mimicry is thought to underlie SARS-CoV-2-related GBS. Antibodies specific to CNS disease are present in GBS cases post SARS-CoV-2, including IgG, anti-GM1, anti-GD1a, and anti-GD1β (Civardi et al., 2020; Dufour et al., 2021). One case of Miller Fisher syndrome with increased pro-inflammatory cytokine markers and positive anti-GD1β-IgG levels has been reported, supporting immune-mediated pathomechanisms (Gutiérrez-Ortiz et al., 2020).

Although it was initially thought that the pandemic would trigger a spike in GBS cases, data has shown otherwise. Instead, three studies CoV-2 era (Keddie et al., 2021; Luijten et al., 2021; Umapathi et al., 2021), positive anti-GD1b-IgG levels has been reported, supporting immune-therapy.

3. SARS-CoV-2 neurotropism

Early in the pandemic, it was shown SARS-CoV-2 leverages the ACE2 receptor to facilitate entry into host cells, like its predecessors, SARS-CoV and Middle East respiratory syndrome coronavirus (Yan et al., 2020). Once the SARS-CoV-2 spike protein receptor-binding domain latches onto ACE2, proximal serine proteases, e.g., transmembrane serine protease 2 (TMPRSS2), cleave the spike-ACE2 complex, internalizing the virus (Fig. 1B) (Hoffmann et al., 2020). Tissue receptor expression dictates tropism; thus, widespread ACE2 expression across multiple tissues results in extensive SARS-CoV-2 tropism. ACE2 expression level in the CNS is moderate (Li et al., 2020a, 2020b); however, since the discovery that SARS-CoV-2 binds ACE2, additional receptors have been identified, including neuropilin-1 (NR1P1), a glycoprotein involved in neurogenesis (Zhang et al., 2021a, 2021b). ACE2 and NR1P1 are widely expressed in the brain; however, ACE2 is most highly expressed in endothelial vasculature and circumventricular organs (Hernández et al., 2021), whereas NR1P1 expression is especially enhanced in the hippocampus, endothelial cells, mural cells, perivascular macrophages, and microglia (Davies et al., 2020).

Several mechanisms have been proposed for viral penetration into the brain. One suggested viral entry route is by disrupting the choroid plexus, thereby compromising the BBB and providing SARS-CoV-2 access to the CNS. The virus also triggers a pro-inflammatory response, which can render the BBB susceptible to damage, leading to immune cell infiltration into the brain along with viral penetration (Tremblay et al., 2020; Solomon, 2021). A possible avenue for dissemination throughout the CNS, once the virus has gained passage into the brain, is through the microvasculature. Autopsy examination of frontal cortex tissue from COVID-19 patients (n = 17) reveals an increase of so-called string vessels versus control tissue (n = 23) (Wenzel et al., 2021). String vessels are empty basement membrane tubes lacking endothelial cells, which are signs of capillary loss. The study found that MPSS, the primary SARS-CoV-2 protease, cleaves host endothelial NEMO (nuclear factor (NF)-κB essential modulator), leading to endothelial cell apoptosis, local hypoxia, and microglial and astrocytic reactivity (Wenzel et al., 2021). Therefore, microvascular pathology and endothelial dysfunction (Varga et al., 2020) in the brain may constitute a significant mode of viral dissemination and neuropathology in the brain.

Anosmia is a prominent symptom of COVID-19 infection, even in relatively mild cases. This promoted a putative mechanism of viral entry into the CNS intranasally through the olfactory epithelium, which expresses ACE2 (Fig. 1C) (Brann et al., 2020) and NR1P1 (Cantuti-Castelvetri et al., 2020). In this proposed mechanism, the olfactory bulb would then serve as a conduit to the CNS, including ACE2-expressing circumventricular organs, such as the subfornical organ (de Melo et al., 2021), which are particularly vulnerable because they are not protected by the BBB. A recent study by Khan et al. of olfactory mucosa and whole olfactory bulb tissue from recently deceased COVID-19 patients (n = 85) detected SARS-CoV-2 primarily in the sustentacular cells of the mucosa (Khan et al., 2021). The virus was not detected in olfactory sensory neurons nor the olfactory bulb parenchyma (Khan et al., 2021), like another study, which only found sparse pathology of olfactory bulbs (Thakur et al., 2021). Thus, overall, an intranasal route into the CNS may be unlikely.

Far fewer studies have investigated SARS-CoV-2 penetration into the CNS, although case reports of peripheral neuropathies are reported within the same timeframe of COVID-19 infection (Padroni et al., 2020; Sedaghat and Karimi, 2020; Tiet and Alsheikh, 2020). PNS damage could occur secondary to SARS-CoV-2-induced inflammation, as occurs in the CNS. Alternatively, drawing parallels to other viruses, SARS-CoV-2 could be internalized into neurons through the endocytic pathway and hijack axonal trafficking to spread along the PNS (Fenrich et al., 2020).

Our understanding of SARS-CoV-2 neurotropism derives from both human, i.e., autopsy, and in vitro and mouse studies. Autopsy reveals invasion of the olfactory epithelium (Khan et al., 2021) and CNS (Khan et al., 2021; Solomon et al., 2021). Analysis of autopsies from three COVID-19 patients demonstrated immunoreactivity against the viral spike protein in cortical neurons and endothelial cells, albeit to variable extents (Song et al., 2021). Cellulard staining was perinuclear along with both intense puncta and diffuse cytoplasmic reactivity; subcortical microscopic ischemic infarcts were also present, which stained for viral proteins in the hyperacute stage. However, although neuroinflammation is a putative characteristic of severe COVID-19 infection, the areas that stained for viral protein were not infiltrated by lymphocytes or
leukocytes (Song et al., 2021), though another autopsy study noted some CD3+, CD4+, and CD8+ T cells in the parenchyma (Schurink et al., 2020).

Analysis of brain autopsy tissue (n = 21) for RNA detected the virus in eight samples, but only at low SARS-CoV-2 copies per cell (Puelles et al., 2020). Another study (n = 18 patients) similarly detected viral RNA in various brain regions in most samples (Solomon et al., 2020).

Interestingly, viral protein was not detected in neurons, glia, endothelium, or immune cells. A larger analysis (n = 40) found both viral RNA and protein in 8 (20%) of brain autopsy samples and either RNA or protein in 21 (53%) specimens (Matschke et al., 2020). One study detected viral RNA, but no protein, in most brain autopsy samples (n = 25), but levels were far lower than in mucosal samples (Thakur et al., 2021). The authors concluded that direct viral neuroinvasion in the brain was unlikely due to the significantly lower viral RNA levels in the brain relative to the nasal epithelium, and that most CNS neuropathology results from systemic inflammation, possibly compounded by local hypoxia and ischemia. It is worth noting that peripheral immune cell infiltration into the CNS has been detected in the brain, but also to variable extents (Schurink et al., 2020; Song et al., 2021), and primarily in the brain stem (Matschke et al., 2020; Thakur et al., 2021).

Another point of consideration, which has limited our understanding of SARS-CoV-2 neurotropism in the brain from autopsy samples, is that sensitivity for detecting viral RNA may be higher than for viral proteins (Solomon et al., 2020; Thakur et al., 2021). However, RNA analysis from bulk brain tissue does not allow localization of the RNA to specific cell types, and the virus detected in the brain may be more prevalent in endothelial cells versus neurons or glia (Nuovo et al., 2021; Wenzel et al., 2021). However, this possibility requires further investigation and single-cell sequencing of brain autopsy tissue may be one path forward (Fullard et al., 2021).

Regarding the PNS, consecutive autopsies (n = 35) from femoral nerve tissue revealed neuritis in nine COVID-19 patients without evidence of direct SARS-CoV-2 invasion, likely indicating inflammatory- or immune-mediated PNS damage rather than tissue tropism (Suh et al., 2021), though further studies are necessary.

Beyond autopsy studies, brain organoids have also expanded our understanding of viral neurotropism (Ng et al., 2021). The first obstacles to viral penetration into the CNS are the BBB and blood-cerebrospinal fluid (CSF) barriers, which regulate entry of material into the brain. The blood-CSF barrier lines the choroid plexus, which produces CSF. Infection rate was significantly higher in choroid plexus (10–20%) versus cortical (<1.5%), hippocampal (<1.0%), hypothalamic (<1.5%), and midbrain (<1.5%) organoids generated from human induced pluripotent stem cells (hiPSCs) (Jacob et al., 2020). Similarly, analysis of cell cultures found choroid plexus epithelial cells were robustly infected with SARS-CoV-2, whereas neurons and astrocytes were sparsely infected. Another study of hiPSC-derived choroid plexus organoids observed higher ACE2 expression by mature choroid plexus cells but not by neurons or other cell types, which mirrored greater SARS-CoV-2 infectivity of choroid cells (13%), but not of neurons or glia (Pellegrini et al., 2020). Additionally, the live virus also structurally and functionally compromised the choroid plexus epithelial barrier, and preference for choroid plexus cells and glia by SARS-CoV-2 over neurons was also reported by McMahon and colleagues (McMahon et al., 2021). Although human studies suggest that viral entry may proceed primarily from systemic inflammation (Solomon, 2021; Thakur et al., 2021), brain organoid studies suggest that direct viral infection and/or destruction of choroid plexus may be feasible. However, if this pathway does occur in vivo, it may be to an insignificant extent.

Some brain organoid studies have observed higher infection of neurons by SARS-CoV-2 (Song et al., 2021; Wang et al., 2021), especially mature, MAP2-positive neurons, leading to neuronal death and loss (Song et al., 2021). A single-cell RNA-seq study identified multiple clusters of neuronal, neuronal progenitor, and radial glial cell populations (Song et al., 2021). Overlap of SARS-CoV-2 transcripts occurred with all cell-types, but to variable extents among the multiple clusters. Viral infection also induced a transcriptomic shift to a hypermetabolic and hypoxic cellular state, indicating that SARS-CoV-2 may be hijacking cellular metabolism to replicate. Differences among brain organoid studies may derive from maturation state of the organoid, since differentiated neurons are more susceptible than neural progenitor cells (Song et al., 2021) and differentiation boosts infection of astrocytes (Wang et al., 2021).

Alternatively, variation in the hiPSC genetic background in genes linked to SARS-CoV-2 susceptibility could give rise to differential infectivity of neurons and various cell-types observed across organoid studies. For instance, the ApoE4 allele is a risk for severe COVID-19 infection (Kuo et al., 2020). Indeed, isogenic hiPSCs expressing ApoE3 versus ApoE4 demonstrates that ApoE4 renders differentiated neurons more prone to SARS-CoV-2 infection (2.1% ApoE4 versus 1.4% ApoE3) and viral-mediated neurite degeneration (Wang et al., 2021). ApoE4 in differentiated astrocytes similarly predisposes them to viral infection and a decrease in soma and process length. Another possibility for discordance in studies of cellular infectivity preference of SARS-CoV-2 is the viral strain. A German study concluded that a Düsseldorf isolate of SARS-CoV-2 preferentially targets neurons versus neuronal progenitor in human derived brain organoids (Raman et al., 2020).

The striking differences between autopsy findings and in vitro brain organoids merits discussion. By and large, viral RNA or protein can be detected in brain tissue from COVID-19 patients, but only to low levels and their localization to specific cell types remains unclear, although endothelial cells may be a favored compartment versus neurons and glia (Nuovo et al., 2021; Wenzel et al., 2021). On the other hand, SARS-CoV-2 infection of neurons, glia, and choroid plexus cells is evident from brain organoid analysis. Several reasons may explain these disparate findings. If the virus does preferentially infect endothelial cells versus neurons and glia, microvasculature may be the preferred target in vivo. However, brain organoids are devoid of a comprehensive vasculature (Jacob et al., 2020; Song et al., 2021), and SARS-CoV-2 may invade neurons and glia in the absence of other targets, such as endothelial cells. Another possibility is differences in the viral load in vitro and in vivo. Brain organoids can be experimentally infected to a specified multiplicity of infection, at a burden that targets neurons and glia. However, the viral burden may be lower in vivo due to the BBB, despite damage from systemic inflammation, occurring at levels that do not infect neurons. Finally, viral attack is dynamic in vivo, and the temporal element is critical. COVID-19 patients may pass away before significant viral replication has occurred into the brain.

Cumulatively, however, human, in vitro, and animal data support invasion into the CNS. Possibly in humans, the dominant pathway is from systemic inflammation, though this does not fully exclude other less significant entry modes. Moreover, endothelial dysfunction in the brain is an important aspect of neuropathology secondary to SARS-CoV-2 infection. Additionally, the determinants of tropism among specific CNS cell-type still requires clarification. Understanding the determinants of infectivity could help identify patients at risk of developing COVID-19-mediated neurological disorders. If genetic background is a potential determinant of infection, it could explain variable susceptibility to SARS-CoV-2-induced neurological complications in COVID-19 patients. Finally, few studies have investigated neuroinvasion into the CNS, though SARS-CoV-2 may induce peripheral nerve damage.

4. SARS-CoV-2-induced disturbance in neuron-glial interactions

4.1. SARS-CoV-2 in the central nervous system

4.1.1. Astrocyte-neuron interactions

The brain is an incredibly complex organ; neurons are aided in their function by supportive glia, comprised primarily of oligodendrocytes, astrocytes, and microglia. Under homeostatic conditions, astrocytes

Neurobiology of Disease 168 (2022) 105715

M.G. Savelieff et al.
contribute structurally to BBB maintenance (Linnerbauer and Rothhammer, 2020) and are thus part of the brain’s first line of defense from invading pathogens, including SARS-CoV-2 (Fig. 2). Astrocytes also form tripartite synapses with neurons, providing support through neurotransmitter regulation and metabolic coupling. Virally induced disruption of astrocyte function could thus impair both neuronal transmission and metabolism (Cotto et al., 2019; Sher et al., 2019).

Pathologic conditions, such as the presence of danger signals from viral invasion, called damage-associated molecular pattern molecules (DAMPs), induce astrogliosis, a neuroprotective phenotype characterized by morphological, transcriptomic, and biochemical reprogramming and glial fibrillary acidic protein (GFAP) upregulation (Fig. 3). However, astrogliosis can serve as a double-edged sword, promoting the disease process through a neurotoxic phenotype (Ding et al., 2021). In a longitudinal study of COVID-19 patients (n = 47) with varying disease severity, moderate and serious COVID-19 infection correlated with elevated plasma GFAP, and severe disease correlated with increased plasma neurofilament light chain (NFL), a marker of intra-axonal neuronal injury (Kanberg et al., 2021). In severe COVID-19 cases, plasma GFAP peaked earlier in the infection course, indicating initial astrogliosis, whereas NFL was persistently elevated, possibly from longer-lasting neuronal damage. Another study of hospitalized COVID-19 patients with (n = 34) and without (n = 94) neurological symptoms found elevated serum NFL levels, independent of neurologic presentation and uncorrelated to CSF NFL levels, possibly reflecting peripheral nerve damage in severe infection (Paterson et al., 2021). Serum NFL levels were not increased in COVID-19 community cases, suggesting mild disease may not produce nerve injury. Unlike some studies, however, GFAP was not prominent in CSF of patients with serious COVID-19, implying astrogliosis-induced neuronal damage may not always be part of SARS-CoV-2 pathophysiology. It is possible, however, that discrepancies between studies also arise from the time course of GFAP release, which is higher earlier in infection, leading to different results depending on when plasma/serum GFAP is sampled. Possibly, astrogliosis may be easier to detect in brain autopsy tissue. Indeed, investigation of brain samples from deceased COVID-19 patients (n = 43) documented astrogliosis through GFAP staining in 37 (86%) of cases (Matschke et al., 2020).

Another primarily astroglial protein, S100B, also has a putative role as a DAMP and correlates with various neural CNS injuries, from traumatic acute brain damage to neurodegenerative diseases (Michetti et al., 2019). In a small longitudinal study of COVID-19 patients with neurological manifestations involving the CNS and cytokine storm (n = 5), elevated serum S100B was coincident with cytokine release in three patients with acute leukoencephalitis. Though small, the study does suggest that cytokine storm correlates with leukoencephalitis, which injures astrocytes and induces BBB leakage (Perrin et al., 2021).

In addition to a shift in astroglial phenotypes, COVID-19 may lead to astrocytic and microglial proliferation, concomitant with a decrease in neuronal density, as noted in a small neurohistopathological study of brain autopsy material (n = 3 COVID-19, n = 3 control) (Boroujeni et al., 2021). The astrocytes and microglia also adopted a pro-inflammatory phenotype, a scenario suggesting inflammation-induced neuronal loss.

### 4.1.2. Microglia-neuron interactions

Microglia are the resident immune cells of the CNS (Prinz et al.,...
During homeostatic conditions in the adult brain, they surveil the CNS milieu for potentially harmful agents, e.g., infectious pathogens, tissue injury (Fig. 2). They also perform numerous “housekeeping” roles, such as clearing the CNS of debris by phagocytosis. Microglia also remodel neuronal circuits by pruning dendritic spines and synapses during learning and memory and participate in axonal myelin maintenance and remyelination. Therefore, microglia have a direct impact on neuronal health. Under pathologic conditions during infection, microglia launch an immune response in order to clear the invading pathogen from the CNS (Fig. 3) (Hatton and Duncan, 2019). This response is complex and involves variably activated microglia with anti- and pro-inflammatory phenotypes (Cherry et al., 2014). Unfortunately, in certain instances, an overly pro-inflammatory state can develop, which is toxic to neurons.

A comparable situation may occur during SARS-CoV-2, with a microglial-mediated local inflammatory response within the CNS, which is compounded by the presence of systemic hyperinflammation that can also spread throughout the brain (Solomon, 2021). Post-mortem evaluation of COVID-19 patients (n = 43) sheds light on this dual inflammatory process in the brain, which demonstrates both microglial activation and cytotoxic T lymphocyte infiltration, mostly in the brainstem and cerebellum (in up to 79% of cases) (Matschke et al., 2020). Analysis of cerebral autopsy samples (n = 3) also demonstrates activation of the NLRP3 inflammasome (Cama et al., 2021), a sensor of pathogen-associated molecular patterns (PAMPs) involved in the anti-viral response (Zhao and Zhao, 2020). NLRP3 colocalizes with CD68+ macrophages in the brain and the periphery (lung) of the deceased, implicating a role for NLRP3 in SARS-CoV-2 pathology (Cama et al., 2021).

Single-nucleus RNA sequencing of brain samples for COVID-19 patients that died from severe infection confirm immunohistological microglia analyses. The brain transcriptome in COVID-19 (n = 8 COVID-19; n = 13 controls) reveals choroid plexus barrier disruption along with signaling cues into the CNS (Yang et al., 2021). Peripheral T cell infiltration is present along with resident microglia, which have adopted a phenotype reminiscent of neurodegenerative disease. Another transcriptomic analysis of three distinct brain areas (n = 5 COVID-19; n = 4 controls) found an influx of monocytes and macrophages in the choroid plexus along with a signature in cortical microglia linked to cellular activation, mobility, and phagocytosis (Fullard et al., 2021). In both instances, molecular traces of SARS-CoV-2 were not detected (Fullard et al., 2021; Yang et al., 2021), possibly suggestive of persistent inflammation and longer-lasting neural injury, even after the virus has cleared. Using a paradigm of spatial profiling by imaging mass cytometry at single-cell resolution, an evaluation was performed of autopsy brain stem and olfactory bulb (Schwabenland et al., 2021). Significant neuropathology was seen, involving axonal damage, astrocytosis, and BBB leakage, concomitant with viral antigens in ACE2+ vascular cells. Pervascular microglial nodules enriched with activated CD8+ T cells were also noted, which correlated with clinical measures of systemic inflammation.

Research of in vitro and in vivo models paints a similar picture. Exposure of rodent BV-2 microglia to SARS-CoV-2 spike protein increases tumor necrosis factor alpha (TNF-α), interleukin-6 (IL-6), IL-1β, and inducible nitric oxide synthase (iNOS)/nitric oxide (NO) production (Ola¡ide et al., 2021). Microglial contact with spike protein also enhanced NLRP3 inflammasome and caspase-1 activity. Similar observations were made following exposure of human HMC3 microglia to...
SARS-CoV-2 spike protein, leading to heightened TNF-α, IL-8, IL-1β, and reactive oxygen species generation and increased NOS and caspase-3/7 expression (Clough et al., 2021). This pro-inflammatory response was accompanied by microglial morphological changes along with mito-chondrial fragmentation. In vivo, in SARS-CoV-2-infected K18-hACE2 transgenic mice (cytokeratin-18 gene promoter driven human ACE2 expression) and Syrian hamsters, microglia proliferated and increased TNF-α and IL-6 expression (Zhang et al., 2021b).

CNS microglia may also be activated by exosomes carrying viral material, rather than the virus itself. Exosomes are extracellular vesicles that bud off from cells and carry cargo to recipient cells. This intercel-lular communication mode can occur as part of normal physiologic function, or as a pathological process during disease states, including a viral infection. Circulating exosomes have been detected in patients in the context of SARS-CoV-2 infection, carrying cargo harboring SARS-CoV-2 RNA and a distinct proteome signature strongly involved in host response to infection, immune processes, inflammation, and coag-ulation (Barberis et al., 2021). It is conceivable that exosomes can penetrate the CNS and activate microglia; indeed, an in vitro study of exosomes derived from HEK293T cells transfected with SARS-CoV-2 spike plasmid were found to transfest human microglial CHME3 cells (Mishra and Banerjea, 2021). Exosome cargo was enriched in micro-RNAs (miR) 148a and miR-590-3p. microRNAs are small non-coding RNAs that negatively regulate expression of target genes. The exo-somes suppressed ubiquitin specific peptidase 33 (USP33) and interferon regulatory factor 9 (IRF9) expression in recipient microglia, the latter being involved in immune regulation.

5. Summary

Overall, human, in vitro, and animal evidence suggests a recurrent theme of astrogliosis and pro-inflammatory microglial activation in SARS-CoV-2 infection in the brain (Fig. 3). Some studies suggest these processes occur in tandem with neuron axonal damage and loss, possibly indicating neuronal injury arising secondary to a breakdown in neuron-glia homeostasis. Future studies are needed to better understand the molecular steps or mediators of neuron-glia or axo-glia communications during SARS-CoV-2 infection leading to brain damage, with the goal of developing mechanism-based therapies. Furthermore, understanding of potential neuron-oligodendrocyte interactions is lacking in the context of SARS-CoV-2. However, a study of another coronavirus, mouse hepatitis virus (MHV), suggests surviving oligodendrocytes post viral infection may prolong the inflammatory phase (Pan et al., 2020).

5.1. SARS-CoV-2 in the peripheral nervous system

In contrast to CNS studies, there is a paucity of reports in the PNS. However, PNS neurotropism is a facet of SARS-CoV-2 pathophysiology as evidenced by the emerging literature linking autoimmune peripheral neuropathies to COVID-19 infection (Padroni et al., 2020; Sedaghat and Karimi, 2020; Tiet and AlShaikh, 2020) and the presence of IgG, anti-GM1, anti-GD1a, and anti-GD1b antibodies (Givardi et al., 2020; Dufour et al., 2021). Elevated serum Nfl hints at PNS damage during severe COVID-19 infection (Paterson et al., 2021). However, mecha-nistic studies in SARS-CoV-2 are lacking, although clinical findings suggest an immune-mediated component, at least in part.

Drawing from other neurotropic viruses, such as MHV, demyelinat-ing strains are transported in a retrograde fashion from the brain via axons, inducing optic neuritis with macrophage infiltration and axonal demyelination and loss (Shindler et al., 2011). Human coronavirus OC43 can also spread via neuron axonal transport machinery (Dubé et al., 2018). Thus, similar modes of spread like MHV and OC43 have been proposed for SARS-CoV-2 (Li et al., 2020b); however, this is speculative, and experimental evidence for SARS-CoV-2 is presently missing. One study reported direct nociceptor infection on dorsal root ganglia by SARS-CoV-2, which suggests potential PNS neurotropism (McFarland et al., 2021). SARS-CoV-2 attack of sensory dorsal root ganglia nociceptors implicates potential pathways for pain during severe COVID-19, and possibly into the PASC post-infection phase.

Overall, more studies are needed and will likely evolve over time as we increase our understanding of PNS disorders secondary to SARS-CoV-2.

6. Potential therapeutic avenues of SARS-CoV-2-mediated neurologic injury

To our knowledge, there is no specific treatment protocol for preven-ting neurological complications in COVID-19 patients. Some neurological conditions that develop from SARS-CoV-2 infection improve without specific treatment or can otherwise be treated per standard of care, e.g., corticosteroids or immunoglobulins for autoimmune encephalitis (Paterson et al., 2020). Overall, therapeutic experi-ence remains limited. Fortunately, current understanding of SARS-CoV-2 pathomechanisms suggests potential therapeutic avenues. First, lowering systemic and neural inflammation through broad-acting anti-inflammatory corticosteroid therapy, for example, could mitigate brain vascular and neural damage. Dexamethasone is part of the present repertoire of therapies being used to treat COVID-19 patients. In an open-label trial, dexamethasone reduced 28-day mortality in hospital-ized COVID-19 patients on respiratory support, e.g., invasive mecha-nical ventilation, oxygen administration, but not in those off of respiratory support (Horby et al., 2021). Whether dexamethasone specifically pre-vents neurological injury from SARS-CoV-2 remains to be seen. Other approaches to lowering systemic inflammation include immunomodu-lating antibodies (Izda et al., 2021), e.g., tocilizumab, sarilumab.

The second potential therapeutic target, that of SARS-CoV-2 invasion and/or neuroinvasion, may be mitigated by blocking viral replication and penetration into cells (Izda et al., 2021). Replication-inhibitors include antivirals, such as remdesivir. Preventing cellular entry can be achieved by binding to the virus spike protein or by blocking the ACE2-protease machinery, which grants the virus entry into cells. Casirivimab and imdevimab are monoclonal antibodies that bind to SARS-CoV-2 spike protein and obstruct ACE-2 binding (Izda et al., 2021). The com-bined casirivimab and imdevimab cocktail is effective in preventive and therapeutic paradigms and lowers the incidence and severity of COVID-19 infection (O’Brien et al., 2021; Weinreich et al., 2021). However, the efficacy of this casirivimab/imdevimab cocktail at preventing neuro-logical complications has not been studied. Other approaches of pre-venting SARS-CoV-2 entry into cells rely on pharmacological inhibition of ACE2-protease machinery (Zhang et al., 2021a). Such approaches have only had mixed success thus far, as with hydroxychloroquine.

Preclinical and clinical research is ongoing, and the need is great for more definitive COVID-19 therapeutics, specifically those aimed at neural protection.

7. Conclusion

It is now clear that SARS-CoV-2 induces a host of acute neurological complications of varying clinical severity. In some instances, these neurologic sequelae evolve into long-term and irreversible complications. As the virus becomes endemic (Emanuel et al., 2022), this could have ramifications for many recovering from COVID-19 infection, although emerging variants may not trigger as much neurological damage as the original and delta variants. Fortunately, the putative mecha-nism of COVID-19 induced acute neurologic injury is becoming more apparent, thus opening the window for therapeutic interventions. These pathologic mechanisms include systemically and locally induced in-flammatory responses and/or endothelial dysfunction, potential direct viral neuroinvasion, astrogliosis, and pro-inflammatory microglial activation, all leading to neuronal injury. Thus, anti-inflammatory and monoclonal antibodies may help prevent or minimize neurologic damage in the context of acute infection, although formal studies are needed.
Moreover, a clearer mechanistic and molecular picture of neurological pathologies in acute SARS-CoV-2 infection may lead to more effective therapies for mitigating neural damage in patients developing PASC (or long covid syndrome) post infection. For these patients, the landscape remains poorly defined, and therapies to date are primarily supportive. In summary, as COVID-19 infections continue to rise, the burden of SARS-CoV-2-induced acute neurologic disorders and PASC will also increase, necessitating a greater understanding of disease pathophysiology to enable the development of mechanism-based therapies targeting both the CNS and PNS.

Declaration of Competing Interest

MGS, ELF, and AMS declare no conflicts of interest.

Acknowledgments

ELF acknowledges funding from the NIH NIDDK (U01DK119083), the Michigan Diabetes Research Center Elizabeth Weisger Caswell Diabetes Institute COVID-19 and Metabolic Disease Grant Program, the Robert E. Nederlander Sr. Program for Alzheimer’s Research, the Andrea and Lawrence A. Wolfe Brain Health Initiative Fund, the Sinai Medical Staff Foundation, and the NeuroNetwork for Emerging Therapies. AMS acknowledges funding from Bristol Myers Squibb, the GBS-CIFD Foundation, NeuroNEXT, and the Foundation for Peripheral Neuropathy.

References

Aladawi, M., Eihl, M., Abu-Eshbeh, B., Abu Jazar, D., Armositi, A., Bayoumi, A., Piccione, E., 2022. Guillain Barre syndrome as a complication of COVID-19: a systematic review. Can J Neurol Sci 49 (1), 38–48.
Barberis, E., Vanella, V.V., Falasca, M., Caneapero, V., Cappellano, G., Raineri, D., Cantuti-Castelvetri, L., Ojha, R., Pedro, L.D., Djannatian, M., Franz, J., Kuivanen, S., van Boroujeni, M.E., Simani, L., Bluyssen, H.A.R., Samadikhah, H.R., Zamanlui Benisi, S., Barberis, E., Vanella, V.V., Falasca, M., Caneapero, V., Cappellano, G., Raineri, D., Staff Foundation, and the NeuroNetwork for Emerging Therapies. AMS and Lawrence A. Wolfe Brain Health Initiative Fund, the Sinai Medical Staff Foundation, and the NeuroNetwork for Emerging Therapies. AMS and Lawrence A. Wolfe Brain Health Initiative Fund, the Sinai Medical Staff Foundation, and the NeuroNetwork for Emerging Therapies.

In summary, as COVID-19 infections continue to rise, the burden of...
Song, H., Carlos de la Torre, J., Ming, G.L., 2020. Human plasmid stem cell-derived neural cells and brain organoids reveal SARS-CoV-2 Neurotropism predominates in epithelial cells. Cell Stem Cell 27 (6), 879–900.e5.e9.

Kanberg, N., Simren, J., Edén, A., Andersson, L.M., Nilsson, S., Ashton, N.J., Sundvall, P.D., Nelligd, B., Blennow, K., Zetterberg, H., Gislén, M., 2021. Neurochemical signs of astrocytic and neuronal injury in acute COVID-19 normalizes during long-term follow-up. EBioMedicine 70, 103512.

Keddie, S., Pakpok, J., Mousle, C., Pipis, M., Machado, P.M., Foster, M., Record, C.J., Brien, M.P., Forleo-Neto, E., Musser, B.J., Isa, F., Chan, K.C., Sarkar, N., Bar, K.J., Lipsich, L., Braunstein, N., Herman, G., Yancopoulos, G.D., Weinreich, D.M., 2021. Cargo release from M protein is a critical mediator of productive virus entry. Cell 187 (24), 6229–6243.e10.

Kronheim, S.J., Perez-Perez, R., Mohseni, R., Kowal, B., DiCioccio, A.T., Stahl, N., Bier, M., Price, M., Vos, W., van der Wel, N.N., van der Valk, P., Bugiani, M., 2020. APOE e4 genotype predicts severe COVID-19 in the UK biobank community. Sci. Transl. Med. 12, eaax796.

Keh, R.Y.S., Fehmi, J., Paterson, R.W., Benjamin, L.A., Mehta, P.R., Brown, R.L., Athauda, D., Ashton, N.J., Legokey, C.A., Ziff, O.J., Heaney, J., Heslegrave, A.J., Beneden, A.L., Blennow, K., Checkley, A.M., Houllain, C.F., Mummyery, C.J., Lunn, M.P., Man, H., Zandi, M.S., Keddie, S., Krom, M., Vinayan Changdarad, D., Solomon, T., Khennan, A., Barker, S., Jager, H.R., Carletti, F., Simister, R., Werring, D.J., Spyer, M.J., Nastouri, E., Gutthier, S., Rosa-Neto, P., Zetterberg, H., Schott, J.M., Johnson, P., Farmer, S.F., Larou, Y., Chuol, H., Tom, M., Lunn, M.P., Spilane, J., Howard, R., Vincent, A., Werring, D.J., Hoskote, C., Jager, H.R., Manji, H., Zandi, M.S., 2020. The emerging spectrum of COVID-19 neurology: clinical, radiological and laboratory findings. Brain 143 (10), 3104–3125.

Keddie, S., Pakpok, J., Mousle, C., Pipis, M., Machado, P.M., Foster, M., Record, C.J., Brien, M.P., Forleo-Neto, E., Musser, B.J., Isa, F., Chan, K.C., Sarkar, N., Bar, K.J., Lipsich, L., Braunstein, N., Herman, G., Yancopoulos, G.D., Weinreich, D.M., 2021. Cargo release from M protein is a critical mediator of productive virus entry. Cell 187 (24), 6229–6243.e10.
Neurobiology of Disease 168 (2022) 105715

Wang, C., Zhang, M., Garcia Jr., G., Tian, E., Cui, Q., Chen, X., Sun, G., Wang, J., von Weyhern, C.H., Kaufmann, I., Neff, F., Kremer, M., 2020. Early evidence of Varga, Z., Flammer, A.J., Steiger, P., Haberecker, M., Andermatt, R., Zinkernagel, A.S., Tremblay, M.E., Madore, C., Bordeleau, M., Tian, L., Verkhratsky, A., 2020. Neuropathobiology of COVID-19: the role for glia. Front. Cell. Neurosci. 14, 592214.

Mehra, M.R., Schuepbach, R.A., Ruschitzka, F., Moch, H., 2020. Endothelial cell basement membrane disruption without tight junctions alteration. Signal Transduct Target Ther 6 (1), 337.

Schwaninger, M., 2021. The SARS-CoV-2 main protease M(pro) causes microvascular brain pathology by cleaving NEMO in brain endothelial cells. Nat. Neurosci. 24 (11), 1522–1533.

Woodhall, M., Mitchell, J.W., Gibbons, E., Healy, S., Waters, P., Huda, S., 2020. Case report: myelin oligodendrocyte glycoprotein antibody-assiated relapse with COVID-19. Front. Neurol. 11, 598531.

Yan, R., Zhang, Y., Li, X., Xia, L., Guo, Y., Zhou, Q., 2020. Structural basis for the recognition of SARS-CoV-2 by full-length human ACE2. Science 367 (6485), 1444–1448.

Yang, A.C., Kern, F., Losada, P.M., Agam, M.R., Maat, C.A., Schmartz, G.P., Fehlmann, T., Stein, J.A., Schau, N., Lee, D.P., Calcuttawala, K., Vest, R.T., Berdnik, D., Lu, N., Hahn, O., Gate, D., McNerney, M.W., Channappa, D., Cobos, I., Ludwig, N., Schulz-Schaefers, W.J., Keller, A., Wyn-Coray, T., 2021. Dysregulation of brain and choroid plexus cell types in severe COVID-19. Nature 595 (7868), 565–571.

Zhang, X., Xiao, M., Zhang, X., Cao, W., Wang, J., Chen, H., Ding, X., Zhao, H., Zhang, H., Wang, C., Zhao, J., Sun, X., Tian, R., Wu, W., Wu, D., Ma, J., Chen, Y., Zhang, D., Xie, J., Yan, X., Zhu, X., Liu, Z., Wang, J., Do, B., Qin, Y., Gao, P., Qin, X., Xu, Y., Zhang, W., Li, T., Zhang, F., Yao, Z., Li, Y., 2020. Coagulopathy and antiphospholipid antibodies in patients with Covid-19. N. Engl. J. Med. 382, e38.

Zhang, Q., Xiang, R., Huo, S., Zhou, Y., Jiang, S., Wang, Q., Yu, F., 2021a. Molecular mechanism of interaction between SARS-CoV-2 and host cells and interventional therapy. Signal Transduct Target Ther 6 (1), 233.

Zhang, L., Zhou, L., Hao, L., Liu, J., Zhu, H., Lv, Q., Liu, R., Chen, W., Tong, W., Wei, Q., Xu, Y., Deng, W., Gao, H., Xue, J., Song, Z., Yu, P., Han, Y., Zhang, Y., Sun, X., Xu, Y., Qin, C., 2021b. SARS-CoV-2 crosses the blood-brain barrier accompanied with basement membrane disruption without tight junctions alteration. Signal Transduct Target Ther 6 (1), 337.

Zhou, C., Zhao, W., 2020. NLRP3 Inflammasome-a key player in antiviral responses. Front. Immunol. 11, 211.

Zubair, A.S., McAlpine, L.S., Gardin, T., Farhadian, S., Kuruvilla, D.E., Spudich, S., 2020. Neuropathogenesis and neurologic manifestations of the coronaviruses in the age of coronavirus disease 2019: a review. JAMA Neurol 77 (8), 1018–1027.